Innovative phage-based antimicrobial therapies to tackle AMR in Horizon Europe projects

Prof. Silvia Angeletti is a Full Professor of Clinical Microbiology at Università Campus Bio-Medico di Roma, with strong expertise in antimicrobial resistance (AMR) and innovative non-conventional antimicrobial strategies, including bacteriophage-based therapies.

Her research interests focus on the development and clinical translation of phage-based approaches as alternative or complementary tools to antibiotics, addressing the urgent need for effective solutions against multidrug-resistant (MDR) pathogens. She works at the interface between microbiology, translational research and clinical application, contributing to the evaluation of efficacy, safety and feasibility of phage-based therapeutics.

Key areas of expertise include:

• Bacteriophage isolation, characterization and host-range assessment

• Phage–bacteria interactions and mechanisms of antibacterial activity

• Phage-based strategies against MDR and difficult-to-treat infections

• In vitro and ex vivo models to evaluate antimicrobial efficacy

• Integration of phage therapy with conventional antimicrobials and stewardship strategies

• Clinical microbiology support for translational and early clinical studies

Prof. Angeletti has experience in multidisciplinary and international collaborations, bridging basic phage research, regulatory considerations and clinical needs. She is particularly interested in participating in Horizon Europe collaborative projects aimed at advancing phage-based antimicrobials from bench to bedside.

She offers expertise as a project partner contributing:

• Clinical microbiology and AMR expertise

• Access to clinically relevant bacterial isolates and MDR strains

• Support for preclinical validation and translational workflows

• Interpretation of microbiological and clinical data for regulatory and clinical readiness

She is open to collaborations addressing:

• Novel phage-based therapeutics and phage-derived products

• Personalized phage therapy and precision antimicrobial approaches

• Combination therapies (phages + antibiotics or adjuvants)

• AMR preparedness and innovative infection control strategies

• One Health perspectives on phage applications

The Campus Bio-Medico of Rome provides a strong clinical and translational research ecosystem, enabling the evaluation and validation of innovative phage-based antimicrobial solutions within Horizon Europe consortia and maximizing their clinical and societal impact.